MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Phase 3
Completed
Conditions
Dengue
Interventions
Biological: Tetravalent Dengue Vaccine (TDV)
Biological: Placebo
First Posted Date
2017-11-14
Last Posted Date
2019-08-15
Lead Sponsor
Takeda
Target Recruit Count
400
Registration Number
NCT03341637
Locations
🇲🇽

Instituto Nacional de Pediatria (INP), Mexico City, Mexico

🇲🇽

Mexico Centre for Clinical Research, Mexico City, Mexico

🇲🇽

Centro de Atencion E Investigacion Medica (CAIMED) Mexico DF, Mexico City, Mexico

and more 2 locations

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Phase 2
Completed
Conditions
Advanced Renal Cell Carcinoma
Interventions
First Posted Date
2017-11-13
Last Posted Date
2021-09-20
Lead Sponsor
Takeda
Target Recruit Count
35
Registration Number
NCT03339219
Locations
🇯🇵

Keio University Hospital, Shinjuku-ku, Tokyo, Japan

🇯🇵

Nagoya University Hospital, Nagoya, Aichi, Japan

🇯🇵

Kyushu University Hospital, Fukuoka, Japan

and more 16 locations

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Phase 1
Completed
Conditions
Healthy Participants and Patients With Narcolepsy
Interventions
Drug: TAK-925
Drug: Placebo
First Posted Date
2017-11-06
Last Posted Date
2021-03-30
Lead Sponsor
Takeda
Target Recruit Count
58
Registration Number
NCT03332784
Locations
🇯🇵

PS Clinic, Fukuoka, Japan

🇯🇵

Hakata Clinic, Fukuoka, Japan

🇯🇵

Sumida Hospital, Sumida-ku, Tokyo, Japan

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

Phase 1
Completed
Conditions
Crohn Disease
Colitis, Ulcerative
Interventions
First Posted Date
2017-11-01
Last Posted Date
2019-09-06
Lead Sponsor
Takeda
Target Recruit Count
16
Registration Number
NCT03329209
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

Completed
Conditions
Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma
First Posted Date
2017-10-31
Last Posted Date
2021-06-25
Lead Sponsor
Takeda
Target Recruit Count
1770
Registration Number
NCT03327571
Locations
🇰🇷

Pusan National University Hospital, Busan, Korea, Republic of

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2017-10-23
Last Posted Date
2019-05-10
Lead Sponsor
Takeda
Target Recruit Count
40
Registration Number
NCT03316976
Locations
🇨🇳

Phase I Clinical Trial Department, Beijing, Beijing, China

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Phase 1
Completed
Conditions
Renal Impairment
Healthy Volunteers
Interventions
Drug: TAK-954
First Posted Date
2017-09-28
Last Posted Date
2020-08-25
Lead Sponsor
Takeda
Target Recruit Count
32
Registration Number
NCT03296787
Locations
🇨🇿

PRA CZ, s.r.o, Praha 7, Praha, Czechia

🇨🇿

Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia

🇭🇺

PRA Magyarorszag Kft., Budapest, Hungary

and more 1 locations

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

Phase 2
Completed
Conditions
Idiopathic Gastroparesis
Diabetic Gastroparesis
Interventions
Drug: TAK-954
Drug: Placebo
First Posted Date
2017-09-13
Last Posted Date
2021-01-07
Lead Sponsor
Takeda
Target Recruit Count
36
Registration Number
NCT03281577
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Phase 1
Completed
Conditions
Hepatic Impairment
Healthy Volunteers
Interventions
Drug: TAK-954
First Posted Date
2017-09-11
Last Posted Date
2019-09-25
Lead Sponsor
Takeda
Target Recruit Count
25
Registration Number
NCT03277274
Locations
🇸🇰

Summit Center of Clinical Research, Bratislava, Slovakia

🇨🇿

PRA CZ, s.r.o, Praha 7, Praha, Czechia

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Phase 3
Completed
Conditions
Myelodysplastic Syndrome
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Interventions
First Posted Date
2017-08-31
Last Posted Date
2024-10-28
Lead Sponsor
Takeda
Target Recruit Count
454
Registration Number
NCT03268954
Locations
🇺🇸

Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Baptist Health System (N Kendall) - USOR, Miami, Florida, United States

and more 199 locations
© Copyright 2025. All Rights Reserved by MedPath